Institution profile

医療法人松樹会 松本クリニック

Explore the institution's name, address and registered technologies as published, along with plan classifications, score components and sources.

The ranking reflects only the registration data published by Japan's Ministry of Health, Labour and Welfare; it does not represent treatment outcomes or quality of care. Scoring method →

Source: Ministry of Health, Labour and Welfare public directory of regenerative medicine providers MHLW e-Regenerative Medicine public register · Directory archive date I: 2026-07-19 / II: 2026-09-26 / III: 2026-05-18 · Internet Archive

MHLW e-Regenerative Medicine public registerPublic document number 01E2410012 +6

Location

Prefecture
Osaka
Address
八尾市南本町4丁目1-11

Plan classification

  • Class INot registered
  • Class IINot registered
  • Class IIIThe low-risk category under the law.

Certified committee for regenerative medicine

  • 日本薬事法務学会再生医療等委員会
  • 患者の集いモミの木再生医療等委員会
  • がん免疫細胞療法審査委員会

Public score

37.5/ 100

A · Review level
10.0 / 30
B · Technologies
23.9 / 35
C · Coverage
3.6 / 25
D · Class I / II technologies
0.0 / 10

The public score is calculated from public registration information and does not reflect quality of care. Scoring method →

Overall ranking

No. 1379of 1736

Registered technologies
7
Areas covered
1

Technology areas · Rank

Position in the overall score distribution

0–100 · Public score
000–9.9 · 0 institutions
01010–19.9 · 0 institutions
2172020–29.9 · 217 institutions
3163030–39.9 · 316 institutions
7564040–49.9 · 756 institutions
2465050–59.9 · 246 institutions
1326060–69.9 · 132 institutions
417070–79.9 · 41 institutions
248080–89.9 · 24 institutions
49090–100 · 4 institutions
This institution 37.5
Public score →100

Registered technologies (7)

NK and immune cells 6
Registered technologies · Japanese originalTechnology areasPlan classification
GMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®)NK and immune cellsClass III
全血採血によるGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®Ⅱ)NK and immune cellsClass III
悪性腫瘍に対する自己活性化NK細胞療法NK and immune cellsClass III
NK細胞を用いる、悪性新生物に対するANK自己リンパ球免疫療法NK and immune cellsClass III
CTLを用いる、悪性新生物に対するCTL療法NK and immune cellsClass III
活性化自己リンパ球療法(別名として、AAT: Aoutologus Activated T-lymphocyte 、αβT細胞療法、CD3-LAK 養子免疫療法)NK and immune cellsClass III
Other 1
Registered technologies · Japanese originalTechnology areasPlan classification
細胞性免疫誘導型DCワクチン Cellular immunity inducing DC (CIi-DC)OtherClass III

Certified committee for regenerative medicine

  • 日本薬事法務学会再生医療等委員会
  • 患者の集いモミの木再生医療等委員会
  • がん免疫細胞療法審査委員会

Public document number

  • 01E2410012
  • 01E2410014
  • 02E2601036
  • 02E2601037
  • 02E2601038
  • 02E2602006
  • 02E2602007
Plan classification · Certified committee for regenerative medicine · Public document number
Registered technologiesPlan classificationCertified committee for regenerative medicinePublic document number
GMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®)Class III日本薬事法務学会再生医療等委員会01E2410012
全血採血によるGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®Ⅱ)Class III日本薬事法務学会再生医療等委員会01E2410014
活性化自己リンパ球療法(別名として、AAT: Aoutologus Activated T-lymphocyte 、αβT細胞療法、CD3-LAK 養子免疫療法)Class III患者の集いモミの木再生医療等委員会02E2601036
悪性腫瘍に対する自己活性化NK細胞療法Class III患者の集いモミの木再生医療等委員会02E2601037
細胞性免疫誘導型DCワクチン Cellular immunity inducing DC (CIi-DC)Class III患者の集いモミの木再生医療等委員会02E2601038
NK細胞を用いる、悪性新生物に対するANK自己リンパ球免疫療法Class IIIがん免疫細胞療法審査委員会02E2602006
CTLを用いる、悪性新生物に対するCTL療法Class IIIがん免疫細胞療法審査委員会02E2602007

Other institutions in the same prefecture

← Institution directory
One-to-one advice

Still unsure? Ask an advisor

Use the “Chat with an advisor” button on this page (at the bottom of the screen on mobile, bottom right on desktop) to open a chat with the Stem Cell Japan advice desk. Consultation and coordination are free, and an advisor replies within one working day.

Chat with an advisor